Cargando…

Editorial: The State-of-Art in Immuno-Oncology, What to Do With Glioblastoma?

Detalles Bibliográficos
Autores principales:	Cui, Xiaoteng, Wang, Qixue, Kang, Chunsheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8579097/ https://www.ncbi.nlm.nih.gov/pubmed/34777399 http://dx.doi.org/10.3389/fimmu.2021.788733

Ejemplares similares

Expert opinion on translational research for advanced glioblastoma treatment
por: Cui, Xiaoteng, et al.
Publicado: (2023)

Editorial: Innovative theranostic approaches towards neuro-immunology in gliomas
por: Cui, Xiaoteng, et al.
Publicado: (2023)

PTRF/Cavin-1 as a Novel RNA-Binding Protein Expedites the NF-κB/PD-L1 Axis by Stabilizing lncRNA NEAT1, Contributing to Tumorigenesis and Immune Evasion in Glioblastoma
por: Yi, Kaikai, et al.
Publicado: (2022)

Mevalonate Metabolism in Immuno-Oncology
por: Gruenbacher, Georg, et al.
Publicado: (2017)

Single-Cell Transcriptomics of Glioblastoma Reveals a Unique Tumor Microenvironment and Potential Immunotherapeutic Target Against Tumor-Associated Macrophage
por: Cui, Xiaoteng, et al.
Publicado: (2021)

SITC 2018 workshop report: Immuno-Oncology Biomarkers: State of the Art
por: Butterfield, Lisa H., et al.
Publicado: (2018)

Editorial: Immuno-Metabolism in Tumor Microenvironment
por: Prado-García, Heriberto, et al.
Publicado: (2017)

Leveraging NKG2D Ligands in Immuno-Oncology
por: Fuertes, Mercedes Beatriz, et al.
Publicado: (2021)

Considerations for the clinical development of immuno-oncology agents in cancer
por: Pandiella, Atanasio, et al.
Publicado: (2023)

Editorial: Immuno-Epigenetic Markers for Infectious Diseases
por: dos Santos, Eduardo José Melo, et al.
Publicado: (2019)

Immuno-oncology: are TAM receptors in glioblastoma friends or foes?
por: Zhou, Yunxiang, et al.
Publicado: (2021)

Putting Proteomics Into Immunotherapy for Glioblastoma
por: Chen, Liangyu, et al.
Publicado: (2021)

Immuno-cardio-oncology: Killing two birds with one stone?
por: Van Linthout, Sophie, et al.
Publicado: (2022)

Greater patient access to immuno-oncology therapies—what can policymakers do?
por: de Lorenzo, Francesco, et al.
Publicado: (2015)

TCA-phospholipid-glycolysis targeted triple therapy effectively suppresses ATP production and tumor growth in glioblastoma
por: Yang, Shixue, et al.
Publicado: (2022)

RUNX1 contributes to the mesenchymal subtype of glioblastoma in a TGFβ pathway-dependent manner
por: Zhao, Kai, et al.
Publicado: (2019)

Quantitative Mechanistic Modeling in Support of Pharmacological Therapeutics Development in Immuno-Oncology
por: Peskov, Kirill, et al.
Publicado: (2019)

Insights into immuno-oncology drug development landscape with focus on bone metastasis
por: Kähkönen, Tiina E., et al.
Publicado: (2023)

Editorial: Immuno-diagnosis of active tuberculosis; are we making progress?
por: Mayanja-Kizza, Harriet, et al.
Publicado: (2023)

A review of spatial profiling technologies for characterizing the tumor microenvironment in immuno-oncology
por: Hu, Bian, et al.
Publicado: (2022)

Editorial: Systems Biology Methods in Computational Immuno-Oncology
por: Rodin, Andrei S., et al.
Publicado: (2022)

Erratum: Editorial: Immuno-diagnosis of active tuberculosis; are we making progress?
Publicado: (2023)

IOBR: Multi-Omics Immuno-Oncology Biological Research to Decode Tumor Microenvironment and Signatures
por: Zeng, Dongqiang, et al.
Publicado: (2021)

(89)Zr-Immuno-Positron Emission Tomography in Oncology: State-of-the-Art (89)Zr Radiochemistry
por: Heskamp, Sandra, et al.
Publicado: (2017)

What nature has to offer: Opportunities for immuno-oncology
por: Kousar, Rubina, et al.
Publicado: (2023)

Immuno-Oncology
por: Chaudhuri, Swapna
Publicado: (2017)

Editorial: Immunoglobulin Glycosylation Analysis: State-of-the-Art Methods and Applications in Immunology
por: Trbojević-Akmačić, Irena, et al.
Publicado: (2022)

Immuno-Oncological Biomarkers for Squamous Cell Cancer of the Head and Neck: Current State of the Art and Future Perspectives
por: De Keukeleire, Stijn J., et al.
Publicado: (2021)

Resident Memory-Like Tumor-Infiltrating Lymphocytes (TIL(RM)): Latest Players in the Immuno-Oncology Repertoire
por: Smazynski, Julian, et al.
Publicado: (2018)

Editorial: State-of-the-Art Research on C1q and the Classical Complement Pathway
por: Kishore, Uday, et al.
Publicado: (2016)

Clinical Effects of Immuno-Oncology Therapy on Glioblastoma Patients: A Systematic Review
por: Najafi, Masoumeh, et al.
Publicado: (2023)

Treatment Progress of Immune Checkpoint Blockade Therapy for Glioblastoma
por: Zhang, Na, et al.
Publicado: (2020)

PTRF/Cavin-1 enhances chemo-resistance and promotes temozolomide efflux through extracellular vesicles in glioblastoma
por: Yang, Eryan, et al.
Publicado: (2022)

Editorial: Surgical oncology in the elderly: the state of the art and future challenges
por: Sperti, Cosimo, et al.
Publicado: (2023)

Radiomics in immuno-oncology
por: Bodalal, Z., et al.
Publicado: (2021)

Immuno‐Oncology in China
por: Lu, Shun, et al.
Publicado: (2019)

The Role of Radiation Oncology in Immuno‐Oncology
por: Meng, Xiangjiao, et al.
Publicado: (2019)

Identification of the E2F1-RAD51AP1 axis as a key factor in MGMT-methylated GBM TMZ resistance
por: Zhou, Junhu, et al.
Publicado: (2023)

LncRNA PRADX-mediated recruitment of PRC2/DDX5 complex suppresses UBXN1 expression and activates NF-κB activity, promoting tumorigenesis
por: Li, Yansheng, et al.
Publicado: (2021)

Age-induced changes in anti-tumor immunity alter the tumor immune infiltrate and impact response to immuno-oncology treatments
por: Sitnikova, Suzanne I., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_fajah2i62d42oe8nfhh4n65rts